There are limited treatment options available to control the progression of vitiligo and most of these treatment options carry the risk of both short term as well as long-term adverse effects. Apremilast has emerged as a promising treatment option in psoriasis and many other cutaneous disorders. We report herein the successful use of oral apremilast therapy in controlling the progression of adult onset vitiligo in 13 patients. The patients had not responded to other systemic treatments earlier. In addition to the control of progression, 8 patients (61.5%) showed some evidence of repigmentation after apremilast therapy. Gastrointestinal adverse effects and headache were the commonest adverse effects reported that led to cessation of treatment in 2 cases. This article is protected by copyright. All rights reserved.